SOURCE: IBC Life Sciences

September 27, 2007 13:15 ET

IBC Life Sciences Presents the 5th Annual International Antibody Therapeutics Conference

Featuring 20 New Case Studies of Antibody Products Now in Development

WESTBOROUGH, MA--(Marketwire - September 27, 2007) - IBC Life Sciences is pleased to announce that the 5th Annual International Antibody Therapeutics conference will return to San Diego, California on December 4-6, 2007. This meeting is held in parallel with the 18th Annual International Antibody Engineering meeting (December 2-6, 2007). Together the meetings will attract more than 700 delegates from around the world.

The 5th Annual International Antibody Therapeutics conference presents a focused look at the preclinical and clinical development of antibody-based drug products, with a program featuring twenty new case studies of antibody products now in development:

--  Clinical Updates of Cancer Therapeutics from Agensys, Amgen, Human
    Genome Sciences, Medarex and Seattle Genetics
--  Clinical-Stage Advances from Abbott Laboratories, Genmab, KaloBios and
    Rinat Laboratories
--  Preclinical Programs from Affitech, Armagen, Biogen Idec, Centocor,
    Micromet, Peregrine Pharmaceuticals and Wyeth
--  Exciting Progress in Antibody Conjugates from Cambridge Antibody
    Technology, Immunogen, Medarex, MedImmune and Target-In

This annual conference provides a platform for clinical updates of therapeutic programs in cancer and other indications, and solutions to problems associated with immunogenicity, glycosylation and effector functions. Plus, attendees will be updated on the current status of the antibody therapeutics market, examine the current intellectual property environment and learn how antibody conjugation is improving the targeting for small and large molecule therapeutics.

Complete details on this meeting can be found at or to receive a press pass or arrange an interview with a speaker, email Dawn O'Connor at

About IBC Life Sciences

IBC Life Sciences is the worldwide leader in scientific, technological and business conferences and courses for the life sciences industry. To develop its programs, IBC actively researches the advancements, technologies and trends impacting and driving the race for new drugs and therapies. No other organization can make claim to the breadth and quality that IBC Life Sciences delivers in each meeting, giving the company recognition around the globe for quality, service and value. For more information, visit:

Contact Information

  • Contact:
    Dawn O'Connor
    IBC Life Sciences
    Email Contact